SCHEMBL16629796

SCHEMBL16629796

CC(C)[Si](C)(C)O[C@H](c1ccc(Cl)nc1)[C@H]1CC[C@@H](Cc2ccc(C(=O)N(C)Cc3cccnc3)cc2)N1C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.36
PDK1 Q15118 7/20 0.34
GRM5 P41594 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TLR8 Q9NR97 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
PDK2 Q15119 2/20 0.32
PDK3 Q15120 2/20 0.32
PDK4 Q16654 2/20 0.32
CETP P11597 1/20 0.32
AGTR2 P50052 2/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
KDM4E B2RXH2 2/20 0.32
RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629791 0.93 ACACB (0.35) ACACBPDK1GRM5GPR119MEN1
SCHEMBL18017452 0.87 AGTR2 (0.33) GPR119CETPAGTR2
SCHEMBL17986572 0.86 GPR119 (0.35) GPR119MEN1KMT2AALDH1A1MAPT
SCHEMBL17986573 0.86 GPR119 (0.35) GPR119MEN1KMT2AALDH1A1MAPT
SCHEMBL16619731 0.86 GPR119 (0.35) GPR119MEN1KMT2AALDH1A1MAPT
SCHEMBL16630571 0.86 JAK2 (0.37) ACACBPDK1GRM5GPR119MEN1
SCHEMBL16619094 0.85 ACACB (0.36) ACACBPDK1GRM5GPR119MEN1
SCHEMBL17986608 0.85 ACACB (0.34) ACACBPDK1GRM5GPR119MEN1
SCHEMBL17986538 0.85 ACACB (0.36) ACACBPDK1GRM5GPR119MEN1
SCHEMBL16629792 0.85 ACACB (0.34) ACACBPDK1GRM5GPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ACACB 2541/4885PDK1 1261/4885GRM5 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.